- Genmab is one of my top picks in healthcare. The company expects to report impressive growth over the remainder of 2022 and beyond.
- Genmab has an imposing pipeline of proprietary and partnered programs that should provide additional growth opportunities.
- Genmab recently publicized that a tribunal was determined by a majority opinion in favor of Janssen Biotech in two disputes relating to DARZALEX.
- The market has changed since my first Genmab article. As a result, I have altered my thesis on GMAB to take advantage of the new market environment.
For further details see:
Genmab: Looking For Growth At A Reasonable Price